Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Approximately 20% of patients with TP53-mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. METHODS: This was a phase Ib/II st...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Sallman, David A., DeZern, Amy E., Garcia-Manero, Guillermo, Steensma, David P., Roboz, Gail J., Sekeres, Mikkael A., Cluzeau, Thomas, Sweet, Kendra L., McLemore, Amy, McGraw, Kathy L., Puskas, John, Zhang, Ling, Yao, Jiqiang, Mo, Qianxing, Nardelli, Lisa, Al Ali, Najla H., Padron, Eric, Korbel, Greg, Attar, Eyal C., Kantarjian, Hagop M., Lancet, Jeffrey E., Fenaux, Pierre, List, Alan F., Komrokji, Rami S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Wolters Kluwer Health 2021
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8099410/
https://ncbi.nlm.nih.gov/pubmed/33449813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02341
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky